Ongoing Trials in T-Cell Lymphomas
Jasmine Zain, MD, from the Center for the Lymphoid Malignancies, Columbia University Medical Center, discusses two ongoing trials in T-cell lymphomas.
Jasmine Zain, MD, from the Center for the Lymphoid Malignancies, Columbia University Medical Center, discusses two ongoing trials in T-cell lymphomas.
Clinical Pearls:
- Researchers are currently working on combining epigenetic therapies for the treatment of T-cell lymphomas
- Vorinostat and romidepsin, which are the only two approved epigenetic therapies in this space, both have response rates close to 30%
- Activity remains to be seen in a phase I trial looking at the combination of romidepsin and 5-azacytidine
- Another trial is observing the activity of pralatrexate in combination with romidepsin
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
